Mobia Medical (MOBI) Corporate presentation summary

Market opportunity and clinical need

• Stroke is a leading cause of long-term disability in the U.S., with over 9 million ischemic stroke survivors and 800,000 new strokes annually.

• Chronic stroke survivors with moderate-to-severe upper extremity impairment represent a large, underserved population, with a $30B+ serviceable U.S. market.

• Recovery plateaus after 3-6 months post-stroke, leaving many patients with persistent disabilities.

VivistimⓇ therapy and clinical evidence

• VivistimⓇ is the first and only FDA-approved, clinically validated intervention for chronic stroke recovery targeting upper limb impairment.

• Therapy uses paired vagus nerve stimulation (VNS) to enhance neuroplasticity and restore hand and arm function.

• Pivotal trials showed 2-3x greater recovery in hand and arm function compared to control, with benefits sustained across subgroups and time since stroke.

• Over 20 publications and ongoing registries support efficacy, safety, and real-world impact.

Patient outcomes and therapy journey

• Real-world cases demonstrate transformative improvements in daily activities and motor function.

• Therapy involves outpatient surgical implantation, followed by in-clinic and at-home rehabilitation paired with stimulation.

• Addressable market includes ~1M strong candidates annually, with ~50K per year based on candidacy factors.